GMC-316

GMC-316 is an experimental small molecule drug candidate developed by Genmedica Therapeutics SL for the treatment of type 2 diabetes. It was identified through the company's proprietary OSIF (Oxidative Stress and Inflammation) technology platform, which focuses on developing orally available compounds that simultaneously target oxidative stress and inflammatory pathways. While the specific molecular targets of GMC-316 have not been publicly disclosed, the drug is part of a metabolic disease portfolio that includes other candidates like GMC-252. As of recent reports, the development status of GMC-316 is listed as pending or in early-stage research, although the developer's official website is currently inactive, suggesting the program may no longer be in active development.